Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6

Xiaomei Li, Ying Huang, Chengfeng Bi, Ji Yuan, Hong He, Hong Zhang, Qiu Bo Yu, Kai Fu, Dan Li

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, whose main prognostic factor is closely related to germinal center B-cell-like subtype (GCB- DLBCL) or activated B-cell-like type (non-GCB-DLBCL). The most common type of primary central nervous system lymphoma is diffuse large B-cell type with poor prognosis and the reason is unclear. This study aims to stratify primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) according to the cell-of-origin (COO) and to investigate the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53, further to elucidate the reason why primary central nervous system diffuse large B-cell lymphoma possesses a poor clinical outcome as well. Nineteen cases of primary central nervous system DLBCL were stratified according to immunostaining algorithms of Hans, Choi and Meyer (Tally) and we investigated the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53. The Epstein-Barr virus and Borna disease virus infection were also detected. Among nineteen cases, most (15–17 cases) were assigned to the activated B-cell-like subtype, highly expression of C-MYC (15 cases, 78.9%), BCL-2 (10 cases, 52.6%), BCL-6 (15 cases, 78.9%). Unfortunately, two cases were positive for PD-L1 while PD-L2 was not expressed in any case. Two cases infected with BDV but no one infected with EBV. In conclusion, most primary central nervous system DLBCLs show an activated B-cell-like subtype characteristic and have multiple expressions of C-MYC, BCL-2, BCL-6 protein, these features might be significant factor to predict the outcome and guide treatment of PCNS-DLBCLs.

Original languageEnglish (US)
Pages (from-to)659-665
Number of pages7
JournalPathology Research and Practice
Volume213
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Central Nervous System
Phenotype
Virus Diseases
Protein C
Human Herpesvirus 4
Borna disease virus
Germinal Center
Non-Hodgkin's Lymphoma

Keywords

  • Activated B-cell-like subtype
  • Algorithms
  • Diffuse large B-cell lymphoma
  • Multiple expressions
  • Primary central nervous system lymphoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6. / Li, Xiaomei; Huang, Ying; Bi, Chengfeng; Yuan, Ji; He, Hong; Zhang, Hong; Yu, Qiu Bo; Fu, Kai; Li, Dan.

In: Pathology Research and Practice, Vol. 213, No. 6, 01.06.2017, p. 659-665.

Research output: Contribution to journalArticle

Li, Xiaomei ; Huang, Ying ; Bi, Chengfeng ; Yuan, Ji ; He, Hong ; Zhang, Hong ; Yu, Qiu Bo ; Fu, Kai ; Li, Dan. / Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6. In: Pathology Research and Practice. 2017 ; Vol. 213, No. 6. pp. 659-665.
@article{0df224a00eab487ab2eeecf9254484cc,
title = "Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, whose main prognostic factor is closely related to germinal center B-cell-like subtype (GCB- DLBCL) or activated B-cell-like type (non-GCB-DLBCL). The most common type of primary central nervous system lymphoma is diffuse large B-cell type with poor prognosis and the reason is unclear. This study aims to stratify primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) according to the cell-of-origin (COO) and to investigate the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53, further to elucidate the reason why primary central nervous system diffuse large B-cell lymphoma possesses a poor clinical outcome as well. Nineteen cases of primary central nervous system DLBCL were stratified according to immunostaining algorithms of Hans, Choi and Meyer (Tally) and we investigated the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53. The Epstein-Barr virus and Borna disease virus infection were also detected. Among nineteen cases, most (15–17 cases) were assigned to the activated B-cell-like subtype, highly expression of C-MYC (15 cases, 78.9{\%}), BCL-2 (10 cases, 52.6{\%}), BCL-6 (15 cases, 78.9{\%}). Unfortunately, two cases were positive for PD-L1 while PD-L2 was not expressed in any case. Two cases infected with BDV but no one infected with EBV. In conclusion, most primary central nervous system DLBCLs show an activated B-cell-like subtype characteristic and have multiple expressions of C-MYC, BCL-2, BCL-6 protein, these features might be significant factor to predict the outcome and guide treatment of PCNS-DLBCLs.",
keywords = "Activated B-cell-like subtype, Algorithms, Diffuse large B-cell lymphoma, Multiple expressions, Primary central nervous system lymphoma",
author = "Xiaomei Li and Ying Huang and Chengfeng Bi and Ji Yuan and Hong He and Hong Zhang and Yu, {Qiu Bo} and Kai Fu and Dan Li",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.prp.2017.02.012",
language = "English (US)",
volume = "213",
pages = "659--665",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "6",

}

TY - JOUR

T1 - Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6

AU - Li, Xiaomei

AU - Huang, Ying

AU - Bi, Chengfeng

AU - Yuan, Ji

AU - He, Hong

AU - Zhang, Hong

AU - Yu, Qiu Bo

AU - Fu, Kai

AU - Li, Dan

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, whose main prognostic factor is closely related to germinal center B-cell-like subtype (GCB- DLBCL) or activated B-cell-like type (non-GCB-DLBCL). The most common type of primary central nervous system lymphoma is diffuse large B-cell type with poor prognosis and the reason is unclear. This study aims to stratify primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) according to the cell-of-origin (COO) and to investigate the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53, further to elucidate the reason why primary central nervous system diffuse large B-cell lymphoma possesses a poor clinical outcome as well. Nineteen cases of primary central nervous system DLBCL were stratified according to immunostaining algorithms of Hans, Choi and Meyer (Tally) and we investigated the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53. The Epstein-Barr virus and Borna disease virus infection were also detected. Among nineteen cases, most (15–17 cases) were assigned to the activated B-cell-like subtype, highly expression of C-MYC (15 cases, 78.9%), BCL-2 (10 cases, 52.6%), BCL-6 (15 cases, 78.9%). Unfortunately, two cases were positive for PD-L1 while PD-L2 was not expressed in any case. Two cases infected with BDV but no one infected with EBV. In conclusion, most primary central nervous system DLBCLs show an activated B-cell-like subtype characteristic and have multiple expressions of C-MYC, BCL-2, BCL-6 protein, these features might be significant factor to predict the outcome and guide treatment of PCNS-DLBCLs.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, whose main prognostic factor is closely related to germinal center B-cell-like subtype (GCB- DLBCL) or activated B-cell-like type (non-GCB-DLBCL). The most common type of primary central nervous system lymphoma is diffuse large B-cell type with poor prognosis and the reason is unclear. This study aims to stratify primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) according to the cell-of-origin (COO) and to investigate the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53, further to elucidate the reason why primary central nervous system diffuse large B-cell lymphoma possesses a poor clinical outcome as well. Nineteen cases of primary central nervous system DLBCL were stratified according to immunostaining algorithms of Hans, Choi and Meyer (Tally) and we investigated the multiple proteins expression of C-MYC, BCL-6, BCL-2, TP53. The Epstein-Barr virus and Borna disease virus infection were also detected. Among nineteen cases, most (15–17 cases) were assigned to the activated B-cell-like subtype, highly expression of C-MYC (15 cases, 78.9%), BCL-2 (10 cases, 52.6%), BCL-6 (15 cases, 78.9%). Unfortunately, two cases were positive for PD-L1 while PD-L2 was not expressed in any case. Two cases infected with BDV but no one infected with EBV. In conclusion, most primary central nervous system DLBCLs show an activated B-cell-like subtype characteristic and have multiple expressions of C-MYC, BCL-2, BCL-6 protein, these features might be significant factor to predict the outcome and guide treatment of PCNS-DLBCLs.

KW - Activated B-cell-like subtype

KW - Algorithms

KW - Diffuse large B-cell lymphoma

KW - Multiple expressions

KW - Primary central nervous system lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85019936885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019936885&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2017.02.012

DO - 10.1016/j.prp.2017.02.012

M3 - Article

VL - 213

SP - 659

EP - 665

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 6

ER -